Intensity Therapeutics Regains Nasdaq Minimum Bid Price Compliance
INTS sits 72% above its 52-week low of $4.633 on light trading volume (0.2× avg).
Summary
Intensity Therapeutics, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, removing the immediate threat of delisting.
Key Events · Corporate Governance and Compliance · INTS
-
Regained Nasdaq Compliance
The company received formal notice from Nasdaq on March 5, 2026, confirming compliance with the minimum bid price requirement (Rule 5550(a)(2)).
-
Delisting Threat Removed
This action resolves the previously disclosed delisting notice issued on June 6, 2025, and its subsequent extension until June 1, 2026.
-
Maintained Bid Price
Compliance was achieved by maintaining a closing bid price of $1.00 or more for 10 consecutive business days, from February 19, 2026, through March 4, 2026.
Analysis · INTS · Life Sciences
This 8-K filing confirms that Intensity Therapeutics has successfully met Nasdaq's minimum bid price requirement by maintaining a closing bid price of $1.00 or more for 10 consecutive business days. This development is highly positive as it resolves a significant compliance issue that had been ongoing since June 2025 and removes the risk of the company's common stock being delisted from The Nasdaq Stock Market. Regaining compliance provides stability and maintains the company's access to a major exchange, which is crucial for investor confidence and liquidity, especially for a company of its size.
At the time of this filing, INTS was trading at $7.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.6M. The 52-week trading range was $4.63 to $62.49. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.